Skip to main content

Opus Genetics, Inc.

IRD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001228627

In the last 90 days, Opus Genetics, Inc. insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $236.4M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Opus Genetics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of IRD: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders381370
Shares2.41M18.0K2.83M+436.6K (+18.3%)
Value$4.62M$35.0K$5.69M+$1.10M (+24.0%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Opus Genetics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to IRD in Q3 2022
InstitutionSharesValue% of portfolio
MAI Capital Management356,948$717.0K0.01%
Dimensional Fund Advisors LP25,576$51.0K0.00%
JPMorgan Chase & Co15,600$31.0K0.00%
Bedel Financial Consulting, Inc.15,000$31.0K0.01%
Susquehanna Fundamental Investments, LLC15,105$30.0K0.00%
Capital Analysts, LLC1,636$3.00K0.00%

Sold out (6)

Institutions that held Opus Genetics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of IRD in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Prelude Capital Management, LLC17,802$34.0K
Citadel Advisors LLC16,458$32.0K
MCF Advisors LLC10,565$20.0K
Kestra Advisory Services, LLC10,005$19.0K
Spire Wealth Management9,002$17.0K
Cutler Group LP200$0

Not filed for Q3 2022 yet (1)

Institutions that held Opus Genetics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding IRD in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Frontier Wealth Management LLC18,000$35.0K